Results 211 to 220 of about 123,362 (289)

Developing a risk score for B-type natriuretic peptide (BNP) ≥ 100 pg/ml levels: the suita study. [PDF]

BMC Cardiovasc Disord
Arafa A, Kato Y, Matsumoto C, Khairan P, Maeda S, Kokubo Y.   +5 more
europepmc   +1 more source

Non‐canonical PKG1 regulation in cardiovascular health and disease

British Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

New biosensors and transgenic mice for multiplex cGMP imaging

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a versatile second messenger that is important for human (patho‐)physiology and pharmacotherapy. Live‐cell imaging of cGMP with biosensors allows to elucidate its spatiotemporal dynamics in real time under close‐to‐native conditions. However, to monitor two separate cGMP pools or cGMP/cAMP
Markus Wolters, Martin Thunemann, Barbara Birk, Susanne Feil, Viacheslav O. Nikolaev, Moritz Lehners, Robert Feil   +6 more
wiley   +1 more source

Action on elevated natriuretic peptide in primary care: a retrospective cohort study. [PDF]

BJGP Open
Vermeer CJ, Hollander M, Stolk AJ, Groenewegen A, Geersing GJ, Rutten FH, Hart HE.   +6 more
europepmc   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

The Effects of the Natriuretic Peptide System on Alveolar Epithelium in Heart Failure. [PDF]

Int J Mol Sci
Knany Y, Kinaneh S, Khoury EE, Zohar Y, Abassi Z, Azzam ZS.   +5 more
europepmc   +1 more source

Effects of Intraaortic Balloon Pump Treatment On Atrial Natriuretic Peptide Levels

, 1995
Bahar Boydak, Osman Nuri Dılek, Hasan Yılmaz, Azem Akıllı, Cüneyt Türkoğlu   +4 more
openalex   +2 more sources

Differential segment‐specific signalling pathways for guanylate cyclase C‐activated anion secretion in murine ileocolon

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Guanylate cyclase‐C (GC‐C) is the receptor for endogenous (uro)guanylin peptides, bacterial toxins and pharmacological analogues. Receptor activation leads to intestinal fluid loss, but also activates an antiproliferative pathway and is a promising target in colorectal cancer therapy.
Renjie Xiu, Johannes Reiner, Franz Hofmann, Azam Salari, Ursula Seidler   +4 more
wiley   +1 more source

Screening Natriuretic Peptide Levels Predicts Heart Failure and Death in Individuals With Type 1 and Type 2 Diabetes Without Known Heart Failure. [PDF]

Diabetes Care
Pop-Busui R, Repetto E, Baron J, Schumacher D, Vaduganathan M, Pandey A.   +5 more
europepmc   +1 more source

Identification of congenital aortic valve malformations in juvenile natriuretic peptide receptor 2-deficient mice using high-frequency ultrasound

Vrushali Guruji, Yuqing Zhou, Mingyi Tang, Zahra Mirzaei, Yu Ding, Malak Elbatarny, Neda Latifi, Craig A. Simmons   +7 more
openalex   +2 more sources